17β-Hydroxysteroid dehydrogenase III deficiency

17β-Hydroxysteroid dehydrogenase III deficiency is a rare disorder of sexual development, or intersex condition, affecting testosterone biosynthesis by 17β-hydroxysteroid dehydrogenase III (17β-HSD III),[6][7] which can produce impaired virilization (historically termed male pseudohermaphroditism) of genetically male infants.[4]

17β-Hydroxysteroid dehydrogenase III deficiency
Other names17 alpha ketosteroid reductase deficiency of testis[1]
Biochemical effects of 17β-hydroxysteroid deficiency-3 in testosterone biosynthesis. Typically levels of androstenedione are significantly increased, whilst testosterone levels are decreased, leading to male undervirilization.
SymptomsHypothyroidism, Cryptorchidism[2]
CausesMutations found in the 17β-HSD III gene[3]
Diagnostic methodGenetic testing[4]
TreatmentGonads should be monitored(possible malignancy)[5]

Signs and symptoms

17-β-Hydroxysteroid dehydrogenase III deficiency is clinically characterized by either ambiguous external genitalia or complete female external genitalia at birth; as a consequence of impaired male sexual differentiation in 46,XY individuals, as well as:[2][6][8]

Genetics

Genetically speaking, 17β-Hydroxysteroid dehydrogenase III deficiency is caused by mutations found in the 17β-HSD III (17BHSD3) gene.17β-HSD III deficiency is an autosomal recessive disorder.[3][9]

Biochemistry
Androstenedione

Androstenedione is produced in the testis, as well as the adrenal cortex. Androstenedione is created from dehydroepiandrosterone (DHEA) or 17-hydroxyprogesterone.[10]

A deficiency in the HSD17B3 gene is characterized biochemically by decreased levels of testosterone and increased levels of androstenedione as a result of the defect in conversion of androstenedione into testosterone. This leads to a clinically important higher ratio of androstenedione to testosterone.[11][3][12]

Diagnosis

In terms of the diagnosis of 17β-hydroxysteroid dehydrogenase III deficiency the following should be taken into account:[4][7]

Management
Further information: Intersex medical interventions

The 2006 Consensus statement on the management of intersex disorders states that individuals with 17β-hydroxysteroid dehydrogenase III deficiency have an intermediate risk of germ cell malignancy, at 28%, recommending that gonads be monitored.[5] A 2010 review put the risk of germ cell tumors at 17%.[13]

The management of 17β-hydroxysteroid dehydrogenase III deficiency can consist, according to one source, of the elimination of gonads prior to puberty, in turn halting masculinization.[7]

Hewitt and Warne state that, children with 17β-hydroxysteroid dehydrogenase III deficiency who are raised as girls often later identify as male, describing a "well known, spontaneous change of gender identity from female to male" that "occurs after the onset of puberty."[14] A 2005 systematic review of gender role change identified the rate of gender role change as occurring in 39–64% of individuals with 17β-hydroxysteroid dehydrogenase III deficiency raised as girls.[15]

Society and culture

Modification of children's sex characteristics to meet social and medical norms is strongly contested, with numerous statements by civil society organizations and human rights institutions condemning such interventions, including describing them as "harmful practices".[16][17][18]

Re: Carla (Medical procedure)

A 2016 case before the Family Court of Australia[19] was widely reported in national,[20][21][22] and international media.[23] The judge ruled that parents were able to authorize the sterilization of their 5-year-old child. The child had previously been subjected to intersex medical interventions including a clitorectomy and labiaplasty, without requiring Court oversight - these were described by the judge as surgeries that "enhanced the appearance of her female genitalia".[19] Organisation Intersex International Australia found this "disturbing", and stated that the case was reliant on gender stereotyping and failed to take account of data on cancer risks.[24]

See also

References
  1. "17-beta hydroxysteroid dehydrogenase 3 deficiency | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 30 July 2019.
  2. "17-beta hydroxysteroid dehydrogenase 3 deficiency | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2017-03-11.
  3. Reference, Genetics Home. "HSD17B3 gene". Genetics Home Reference. Retrieved 11 March 2017.
  4. "Testosterone 17-beta-dehydrogenase deficiency - Conditions - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-03-17.
  5. Lee P. A.; Houk C. P.; Ahmed S. F.; Hughes I. A. (2006). "Consensus statement on management of intersex disorders". Pediatrics. 118 (2): e488–500. doi:10.1542/peds.2006-0738. PMC 2082839. PMID 16882788.
  6. Reference, Genetics Home. "17-beta hydroxysteroid dehydrogenase 3 deficiency". Genetics Home Reference. Retrieved 2017-03-11.
  7. "OMIM Entry - # 264300 - 17-BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY". omim.org. Retrieved 2017-03-11.
  8. "46, XY disorders of sexual development | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 11 March 2017.
  9. RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: 46,XY disorder of sex development due to 17 beta hydroxysteroid dehydrogenase 3 deficiency". www.orpha.net. Retrieved 2017-03-12.
  10. Pubchem. "androstenedione | C19H26O2 - PubChem". pubchem.ncbi.nlm.nih.gov. Retrieved 2017-03-17.
  11. "HSD17B3 hydroxysteroid 17-beta dehydrogenase 3 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-03-13.
  12. "OMIM Entry - * 605573 - 17-BETA HYDROXYSTEROID DEHYDROGENASE III; HSD17B3". omim.org. Retrieved 2017-03-13.
  13. Pleskacova, J.; Hersmus, R.; Oosterhuis, J.W.; Setyawati, B.A.; Faradz, S.M.; Cools, M.; Wolffenbuttel, K.P.; Lebl, J.; Drop, S.L.; Looijenga, L.H. (2010). "Tumor Risk in Disorders of Sex Development". Sexual Development. 4 (4–5): 259–269. doi:10.1159/000314536. ISSN 1661-5433. PMID 20558977.
  14. Hewitt, Jacqueline K.; Warne, Garry L. (February 2009). "Management of disorders of sex development". Pediatric Health. 3 (1): 51–65. doi:10.2217/17455111.3.1.51. ISSN 1745-5111.
  15. Cohen-Kettenis, Peggy T. (August 2005). "Gender Change in 46,XY Persons with 5α-Reductase-2 Deficiency and 17β-Hydroxysteroid Dehydrogenase-3 Deficiency". Archives of Sexual Behavior. 34 (4): 399–410. doi:10.1007/s10508-005-4339-4. ISSN 0004-0002. PMID 16010463.
  16. Office of the High Commissioner for Human Rights (October 24, 2016). "Intersex Awareness Day – Wednesday 26 October. End violence and harmful medical practices on intersex children and adults, UN and regional experts urge".
  17. Report of the UN Special Rapporteur on Torture, Office of the UN High Commissioner for Human Rights, February 2013.
  18. Council of Europe; Commissioner for Human Rights (April 2015), Human rights and intersex people, Issue Paper
  19. Re: Carla (Medical procedure) [2016] FamCA 7 (20 January 2016), Family Court (Australia).
  20. Overington, Caroline (December 7, 2016). "Family Court backs parents on removal of gonads from intersex child". The Australian.
  21. Overington, Caroline (December 8, 2016). "Carla's case ignites firestorm among intersex community on need for surgery". The Australian.
  22. Copland, Simon (December 15, 2016). "The medical community's approach to intersex people is still primarily focused on 'normalising' surgeries". SBS. Retrieved 2017-02-05.
  23. Dunlop, Greg (December 7, 2016). "Australian court approves intersex child's surgery". BBC News.
  24. Carpenter, Morgan (December 8, 2016). "The Family Court case Re: Carla (Medical procedure) [2016] FamCA 7". Organisation Intersex International Australia. Retrieved 2017-02-02.

Further reading
Classification
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.